Skip to main content

Advertisement

SpringerLink
Log in

Receptor combinations hone T-cell therapy

  • News & Views
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The safety of engineered T cells is improved through gated expression of two chimeric antigen receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Cancer-cell-specific T-cell activation by dual-tumor antigen targeting to reduce toxicity.

References

  1. Roybal, K.T. et al. Cell 164, 770–779 (2016).

    Article  CAS  Google Scholar 

  2. Gross, G. & Eshhar, Z. Annu. Rev. Pharmacol. Toxicol. 56, 59–83 (2016).

    Article  CAS  Google Scholar 

  3. Hinrichs, C.S. & Restifo, N.P. Nat. Biotechnol. 31, 999–1008 (2013).

    Article  CAS  Google Scholar 

  4. Linette, G.P. et al. Blood 122, 863–871 (2013).

    Article  CAS  Google Scholar 

  5. Maude, S.L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).

    Article  Google Scholar 

  6. Obenaus, M. et al. Nat. Biotechnol. 33, 402–407 (2015).

    Article  CAS  Google Scholar 

  7. Blankenstein, T., Leisegang, M., Uckert, W. & Schreiber, H. Curr. Opin. Immunol. 33, 112–119 (2015).

    Article  CAS  Google Scholar 

  8. Leisegang, M., Kammertoens, T., Uckert, W. & Blankenstein, T. J. Clin. Invest. 126, 854–858 (2016).

    Article  Google Scholar 

  9. Wilkie, S. et al. J. Clin. Immunol. 32, 1059–1070 (2012).

    Article  CAS  Google Scholar 

  10. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Nat. Biotechnol. 31, 71–75 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thomas Blankenstein is at the Max-Delbrck-Center for Molecular Medicine, Berlin, Germany, and the Institute of Immunology, Charité Campus Buch, Berlin, Germany.,

    Thomas Blankenstein

Authors
  1. Thomas Blankenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Blankenstein.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blankenstein, T. Receptor combinations hone T-cell therapy. Nat Biotechnol 34, 389–391 (2016). https://doi.org/10.1038/nbt.3539

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3539

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation